https://mindmedicinelaw.com/briefing/missouri-s-first-ketamine-clinic-a-new-era-in-psychedelic-therapy-20260823-35067The Psychedelic Journalen2026-08-23T22:03:49.668329+00:00Missouri's First Ketamine Clinic: A New Era in Psychedelic Therapyketamine therapy, psychedelic treatments, Missouri clinic, mental health, psychedelic-assisted therapy, NMDA receptors, depression treatment, PTSD therapy, psychedelic research, ketamine clinichttps://mindmedicinelaw.com/briefing/psilocybin-s-potential-in-treating-depression-a-new-review-20260822-34835The Psychedelic Journalen2026-08-23T15:04:19.843925+00:00Psilocybin's Potential in Treating Depression: A New Reviewpsilocybin, depression treatment, major depressive disorder, psychedelic therapy, treatment-resistant depression, clinical trials, neuroscience, public health, mental health, antidepressant responsehttps://mindmedicinelaw.com/briefing/psilocybin-s-differential-impact-on-autism-new-insights-20260822-34805The Psychedelic Journalen2026-08-23T15:04:10.800060+00:00Psilocybin's Differential Impact on Autism: New Insightspsilocybin, autism spectrum disorders, brain networks, functional connectivity, clinical trials, psychedelic research, neurodevelopmental conditions, therapeutic potential, resting-state fMRI, King's College Londonhttps://mindmedicinelaw.com/briefing/federal-audit-criticizes-kansas-on-parity-compliance-20260821-34806The Psychedelic Journalen2026-08-23T15:04:43.755391+00:00Federal Audit Criticizes Kansas on Parity ComplianceKansas Medicaid, parity compliance, OIG audit, mental health access, psychedelic therapies, behavioral health services, Medicaid MCOs, federal parity laws, mental health policy, treatment barriershttps://mindmedicinelaw.com/briefing/psilocybin-user-outcomes-in-oregon-colorado-insights-implications-20260821-34917The Psychedelic Journalen2026-08-23T15:04:30.641937+00:00Psilocybin User Outcomes in Oregon & Colorado: Insights & Implicationspsilocybin outcomes, Oregon psilocybin, Colorado psychedelics, real-world psilocybin use, psychedelic policy, psilocybin effects, psilocybin risks, psilocybin research, psychedelic therapy, public health strategieshttps://mindmedicinelaw.com/briefing/ketamine-s-metabolic-safety-in-mood-disorder-treatment-20260821-34537The Psychedelic Journalen2026-08-22T22:04:57.064670+00:00Ketamine's Metabolic Safety in Mood Disorder Treatmentketamine, appetite, treatment-resistant mood disorders, metabolic safety, clinical trials, depression treatment, bipolar disorder, psychiatric medication, Visual Analog Scales, Simplified Nutritional Appetite Questionnairehttps://mindmedicinelaw.com/briefing/triptally-a-new-tool-for-estimating-psychedelic-therapy-costs-20260821-34523The Psychedelic Journalen2026-08-22T22:04:08.263473+00:00TripTally: A New Tool for Estimating Psychedelic Therapy Costspsychedelic therapy, cost estimation, TripTally, labor costs, FDA approval, economic planning, resource allocation, clinical trialshttps://mindmedicinelaw.com/briefing/cb1-allosteric-modulation-therapeutic-potential-risks-20260821-34538The Psychedelic Journalen2026-08-22T22:04:00.940033+00:00CB1 Allosteric Modulation: Therapeutic Potential & RisksCB1 allosteric modulators, therapeutic potential, misuse liability, pain relief, addiction treatment, THC alternatives, neuropathic pain, pharmacological profiles, endocannabinoid systemhttps://mindmedicinelaw.com/briefing/enhancing-causal-inference-in-psychedelic-trials-20260821-34524The Psychedelic Journalen2026-08-22T22:03:53.293437+00:00Enhancing Causal Inference in Psychedelic Trialspsychedelic research, clinical trials, causal inference, pretreatment expectancy, double-blind procedure, active placebo, crossover trial, ethical considerationshttps://mindmedicinelaw.com/briefing/oregon-s-psilocybin-program-early-outcomes-and-implications-20260821-34766The Psychedelic Journalen2026-08-22T22:03:36.463931+00:00Oregon's Psilocybin Program: Early Outcomes and ImplicationsOregon psilocybin program, psychedelic therapy, psilocybin treatment, mental health, state-sanctioned psychedelics, Oregon Health Authority, Measure 109, regulated psychedelic use, therapeutic potential, psilocybin policyhttps://mindmedicinelaw.com/briefing/mdma-for-neuropathic-pain-calls-for-phase-2-3-trials-20260821-34511The Psychedelic Journalen2026-08-22T15:05:55.401104+00:00MDMA for Neuropathic Pain: Calls for Phase 2/3 TrialsMDMA, neuropathic pain, clinical trials, neuroplasticity, pain management, Phase 2/3 trials, neurobiology, pain pathways, BDNF, safety considerationshttps://mindmedicinelaw.com/briefing/ohsu-psilocybin-study-implications-for-anxiety-depression-ptsd-20260821-34605The Psychedelic Journalen2026-08-22T15:05:45.199479+00:00OHSU Psilocybin Study: Implications for Anxiety, Depression, PTSDOHSU psilocybin study, psilocybin anxiety treatment, depression and psilocybin, PTSD psychedelic therapy, psilocybin clinical trials, mental health psychedelics, psilocybin regulatory implications, psilocybin serotonin interactionhttps://mindmedicinelaw.com/briefing/mdma-for-neuropathic-pain-clinical-trial-blueprint-20260821-34510The Psychedelic Journalen2026-08-22T15:05:34.173932+00:00MDMA for Neuropathic Pain: Clinical Trial BlueprintMDMA, neuropathic pain, clinical trials, neuroplasticity, pain management, monoamine transporters, oxytocin, BDNF, safety considerations, active placebohttps://mindmedicinelaw.com/briefing/jama-study-evaluates-oregon-s-psilocybin-services-model-20260821-34522The Psychedelic Journalen2026-08-22T15:05:24.312748+00:00JAMA Study Evaluates Oregon's Psilocybin Services ModelOregon psilocybin model, JAMA study, psychedelic-assisted therapy, state-regulated psilocybin, clinical trials, policy implications, psilocybin risks, mental health, therapeutic efficacy, regulatory frameworkshttps://mindmedicinelaw.com/briefing/trump-s-executive-order-boosts-psychedelic-research-20260821-34608The Psychedelic Journalen2026-08-22T15:05:00.481939+00:00Trump's Executive Order Boosts Psychedelic Researchpsychedelic research, executive order, Trump, clinical trials, mental health, FDA, NIH, psilocybin, MDMA, public health policyhttps://mindmedicinelaw.com/briefing/visuomotor-mismatch-eeg-responses-implications-for-neuroscience-20260820-34526The Psychedelic Journalen2026-08-23T15:05:29.958378+00:00Visuomotor Mismatch EEG Responses: Implications for Neurosciencevisuomotor mismatch, EEG responses, predictive coding, neuroscience research, clinical trials, human cortexhttps://mindmedicinelaw.com/briefing/60-hz-light-therapy-for-depression-phase-2-trial-insights-20260820-34539The Psychedelic Journalen2026-08-23T15:05:21.201283+00:0060-Hz Light Therapy for Depression: Phase 2 Trial Insights60-Hz light therapy, major depressive disorder, non-pharmacological treatment, clinical trials, neuroscience, mental health policy, flickering white light, depression treatment, neural oscillations, integrative mental healthhttps://mindmedicinelaw.com/briefing/insulin-resistance-and-depression-new-treatment-insights-20260820-34544The Psychedelic Journalen2026-08-23T15:05:10.238079+00:00Insulin Resistance and Depression: New Treatment Insightsinsulin resistance, major depressive disorder, metabolic dysfunction, treatment-resistant depression, precision medicine, obesity and depression, HPA axis dysfunction, inflammation and depression, insulin pathways, personalized medicinehttps://mindmedicinelaw.com/briefing/psychedelic-therapies-for-nevada-veterans-impacts-and-challenges-20260820-34606The Psychedelic Journalen2026-08-23T15:05:00.964237+00:00Psychedelic Therapies for Nevada Veterans: Impacts and Challengespsychedelics, Nevada veterans, mental health, PTSD treatment, psychedelic policy, clinical trials, first responders, psilocybin, MDMA therapy, veteran supporthttps://mindmedicinelaw.com/briefing/neuromodulation-s-role-in-treating-resistant-depression-20260820-34542The Psychedelic Journalen2026-08-23T15:04:52.139584+00:00Neuromodulation's Role in Treating Resistant Depressiontreatment-resistant depression, neuromodulation, electroconvulsive therapy, repetitive transcranial magnetic stimulation, intermittent theta-burst stimulation, vagus nerve stimulation, deep brain stimulation, clinical positioning framework, equitable access, multidisciplinary carehttps://mindmedicinelaw.com/briefing/psilocybin-s-potential-for-refractory-behavioral-conditions-20260820-34490The Psychedelic Journalen2026-08-22T22:04:28.391010+00:00Psilocybin's Potential for Refractory Behavioral Conditionspsilocybin, mental health treatment, serotonin receptors, regulatory constraints, federal funding, biosynthetic production, psychotherapy integration, clinical trials, substance use disorders, neuroplasticityhttps://mindmedicinelaw.com/briefing/psilocybin-s-impact-on-hippocampal-sharp-wave-ripples-20260820-34525The Psychedelic Journalen2026-08-22T22:04:15.845467+00:00Psilocybin's Impact on Hippocampal Sharp Wave Ripplespsilocybin, hippocampal sharp wave ripples, memory consolidation, neural plasticity, serotonergic receptors, depression treatment, anxiety treatment, sleep architecture, therapeutic applications, psychedelic researchhttps://mindmedicinelaw.com/briefing/psilocybin-therapy-alters-personality-in-alcohol-use-disorder-20260820-34765The Psychedelic Journalen2026-08-22T22:03:45.474392+00:00Psilocybin Therapy Alters Personality in Alcohol Use Disorderpsilocybin therapy, alcohol use disorder, clinical trial, personality changes, psychedelic research, mental health treatment, serotonin receptors, psychedelic-assisted therapyhttps://mindmedicinelaw.com/briefing/inflammation-s-role-in-depression-insights-challenges-20260819-34857The Psychedelic Journalen2026-08-23T22:04:16.034060+00:00Inflammation's Role in Depression: Insights & Challengesinflammation, major depressive disorder, CRP levels, precision medicine, biomarker stratification, anti-inflammatory treatments, clinical trials, neurotransmission, blood-brain barrier, neuroplasticityhttps://mindmedicinelaw.com/briefing/challenges-in-ehr-based-risk-models-for-trd-across-health-systems-20260819-34547The Psychedelic Journalen2026-08-23T22:04:07.862572+00:00Challenges in EHR-Based Risk Models for TRD Across Health Systemstreatment-resistant depression, electronic health records, risk models, transportability, clinical heterogeneity, data biases, health systems, predictive modeling, EHR limitations, TRDhttps://mindmedicinelaw.com/briefing/advances-in-rtms-for-psychiatric-disorders-challenges-and-future-directions-20260819-34548The Psychedelic Journalen2026-08-23T22:03:59.926146+00:00Advances in rTMS for Psychiatric Disorders: Challenges and Future Directionsrepetitive transcranial magnetic stimulation, psychiatric disorders, clinical efficacy, standardized parameters, biomarkers, multicenter trials, neuro-navigation, personalized treatment, brain stimulation, mental healthhttps://mindmedicinelaw.com/briefing/dextromethorphan-bupropion-new-hope-for-mdd-treatment-20260819-34546The Psychedelic Journalen2026-08-23T15:05:39.943503+00:00Dextromethorphan-Bupropion: New Hope for MDD Treatmentdextromethorphan, bupropion, major depressive disorder, mouse model, preclinical study, multimodal therapy, neurotransmitter imbalance, clinical trials, NMDA receptor, neurotrophic supporthttps://mindmedicinelaw.com/briefing/psilocybin-microdosing-systematic-review-highlights-gaps-20260819-34491The Psychedelic Journalen2026-08-22T22:04:47.986376+00:00Psilocybin Microdosing: Systematic Review Highlights Gapspsilocybin microdosing, systematic review, randomized controlled trials, mental health, safety profile, dosing protocols, adverse events, clinical practice, policy-making, conflicts of interesthttps://mindmedicinelaw.com/briefing/trump-s-psychedelic-plan-for-veterans-policy-implications-20260819-34767The Psychedelic Journalen2026-08-22T22:04:38.281745+00:00Trump's Psychedelic Plan for Veterans: Policy Implicationspsychedelic therapies, veterans mental health, Trump policy, PTSD treatment, federal drug policy, FDA psychedelic research, MDMA therapy, psilocybin research, mental health policy, veterans healthcarehttps://mindmedicinelaw.com/briefing/psilocybin-alters-brain-burst-firing-via-5-ht2a-circuits-20260819-34527The Psychedelic Journalen2026-08-22T15:06:07.183479+00:00Psilocybin Alters Brain Burst Firing via 5-HT2A Circuitspsilocybin, 5-HT2A receptor, burst firing, brain circuit dynamics, psychedelic research, therapeutic mechanisms, neuroscience, clinical trialshttps://mindmedicinelaw.com/briefing/oregon-psilocybin-services-safety-and-mental-health-outcomes-20260819-34492The Psychedelic Journalen2026-08-22T15:05:13.224107+00:00Oregon Psilocybin Services: Safety and Mental Health OutcomesOregon psilocybin services, mental health outcomes, psilocybin therapy, state-regulated psychedelics, depression and anxiety treatment, psilocybin safety, therapeutic benefits of psilocybin, psychedelic research, policy implications, clinical practicehttps://mindmedicinelaw.com/briefing/ketamine-and-esketamine-for-post-op-pain-in-gynecological-surgery-20260818-34864The Psychedelic Journalen2026-08-23T22:04:26.271229+00:00Ketamine and Esketamine for Post-Op Pain in Gynecological Surgeryketamine, esketamine, postoperative pain, gynecological surgery, opioid alternatives, perioperative analgesia, Cochrane review, pain management, clinical trials, subanaesthetic doseshttps://mindmedicinelaw.com/briefing/long-term-safety-of-ketamine-in-treatment-resistant-depression-20260817-34553The Psychedelic Journalen2026-08-22T15:06:16.592669+00:00Long-term Safety of Ketamine in Treatment-resistant Depressionketamine, esketamine, treatment-resistant depression, long-term safety, systematic review, clinical trials, neurocognitive effects, iatrogenic addiction, organ toxicity, transient side effectshttps://mindmedicinelaw.com/briefing/fanon-s-insights-on-psychedelics-for-racialized-therapy-20260815-34495The Psychedelic Journalen2026-08-23T22:04:35.007223+00:00Fanon's Insights on Psychedelics for Racialized Therapypsychedelic therapy, Frantz Fanon, racialized individuals, anti-colonial frameworks, systemic racism, MDMA-assisted therapy, cultural sensitivity, equitable treatment, psychedelic research, colonial traumahttps://mindmedicinelaw.com/briefing/iv-ketamine-for-adolescent-depression-efficacy-and-safety-20260815-34554The Psychedelic Journalen2026-08-22T15:06:40.027945+00:00IV Ketamine for Adolescent Depression: Efficacy and Safetyintravenous ketamine, adolescent depression, major depressive disorder, treatment-resistant depression, meta-analysis, antidepressant effects, clinical trials, safety and efficacy, psychiatric treatment, neurosciencehttps://mindmedicinelaw.com/briefing/ai-s-role-in-psychedelic-therapy-relational-competence-issues-20260814-34497The Psychedelic Journalen2026-08-22T15:06:50.704495+00:00AI's Role in Psychedelic Therapy: Relational Competence IssuesAI in psychedelic therapy, relational competence, facilitator training, policy challenges, therapeutic alliance, accreditation infrastructure, equity in therapy, psychedelic trials, AI tools in therapy, ketamine-assisted psychotherapyhttps://mindmedicinelaw.com/briefing/psychologists-personal-mdma-use-influences-therapy-attitudes-20260813-34514The Psychedelic Journalen2026-08-23T22:04:43.925600+00:00Psychologists' Personal MDMA Use Influences Therapy AttitudesMDMA-assisted therapy, psychologists' attitudes, personal MDMA use, evidence-based education, mental health treatment, therapeutic biases, MDMA-AT risks, clinical objectivity, therapeutic integration, healthcare professional training